IDEAYA Biosciences, Inc.

NasdaqGS:IDYA Stock Report

Market Cap: US$2.9b

IDEAYA Biosciences Balance Sheet Health

Financial Health criteria checks 6/6

IDEAYA Biosciences has a total shareholder equity of $935.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $961.5M and $26.2M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$698.77m
EquityUS$935.31m
Total liabilitiesUS$26.22m
Total assetsUS$961.53m

Recent financial health updates

Recent updates

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Feb 22
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Feb 16

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

Jul 04
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Mar 10
We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data

Oct 06

Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering

Sep 14

Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials

Aug 29

Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%

Aug 25
Analysts Have Just Cut Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Estimates By 6.2%

IDEAYA Biosciences GAAP EPS of -$0.57 misses by $0.05, revenue of $11.34M beats by $4.75M

Aug 15

IDEAYA, Amgen in clinical trial deal for small molecule cancer agent

Jul 27

Ideaya: Next 6 Months Critical For Precision Oncology Biotech

Jun 16

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

May 16
Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Apr 12
We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

IDEAYA Biosciences EPS beats by $0.01, misses on revenue

May 10

Financial Position Analysis

Short Term Liabilities: IDYA's short term assets ($709.4M) exceed its short term liabilities ($25.0M).

Long Term Liabilities: IDYA's short term assets ($709.4M) exceed its long term liabilities ($1.3M).


Debt to Equity History and Analysis

Debt Level: IDYA is debt free.

Reducing Debt: IDYA had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IDYA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IDYA has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 33% each year


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.